DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
FOX News on MSN1h
If Biden could pardon Hunter, he should ‘pardon Trump,’ political strategist says
Panelists Lindy Li, Siaka Massaquoi and Erin Perrine join ‘Fox News @ Night’ to discuss the top political headlines from the ...
Athlon Sports on MSN2d
Hunter on Fall Camp
Washington senior wide receiver Jeremiah Hunter speaks during fall camp about why he chose UW and his thoughts on the new ...
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Denali Therapeutics announces U.S. FDA BTD granted for tividenofusp
Denali Therapeutics (DNLI) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
Why biotech startup Tenvie sees promise in drugs from founders' old company
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for ...
Do you have HMPV? The symptoms to check for as the Chinese virus spreads
A viral outbreak in China sounds alarmingly familiar to 2019, back in the days before most of us had ever heard of the ...
Global Mucopolysaccharidosis Treatment Market To Witness Robust Growth, Projected To Reach USD 5,014.5 Million By 2035 Growing At A CAGR Of 5.9% | FMI
The global robotic catheterization systems market opportunity are estimated to be worth USD 54.4 million in 2025 and anticipated to reach a value of USD 190.2 million by 2035. Sales are projected to ...
The American Spectator1d
Media Commentators Seek to Regain Trust: It Won’t Work
In the wake of the debacle known as the Biden presidency, certain media commentators who supported Biden and looked the other ...